FutureMeds is the only European DCT-augmented dedicated research site network that offers precision patient engagement and strong local healthcare system partnerships to create winning business outcomes for performance-conscious clients by providing reliability, efficiency and accuracy, resulting in quality endpoints and reassurance, leaving our clients with increased chances of delivering on targets within budget and timeframe.  

Our 60+ investigators with strong previous experience and capabilities to conduct vaccine trials have randomized 4150+ patients across 32 vaccine trials to date.